Where every Stargardt disease treatment stands now: the first drug under FDA review, the pills and gene therapies in trials, and what you can do today.
Request a Consultation
Last updated: November 21, 2026
No treatment is approved yet for Stargardt disease, the most common inherited macular dystrophy1,2. That may change soon. The FDA is reviewing tinlarebant, a daily pill, and has set a decision date of February 12, 20273. Other pills, gene therapies and an RNA-editing treatment are in clinical trials2.
Each status below was checked on November 21, 2026 against company announcements, ClinicalTrials.gov and FDA records, and this page is updated after FDA decisions and major trial results. Results described as company-reported have not been published in a peer-reviewed journal. For symptoms, causes and diagnosis, see our Stargardt disease guide.
| Treatment | Who it is for | Stage on November 21, 2026 | Next milestone | Trial record |
|---|---|---|---|---|
| Tinlarebant (LBS-008), Belite Bio. Daily pill | Stargardt disease type 1 (ABCA4). The main trial enrolled ages 12 to 204 | Under FDA priority review3 | FDA decision due February 12, 20273 | NCT05244304 |
| Gildeuretinol (ALK-001), Alkeus Pharmaceuticals. Daily pill | Advanced Stargardt disease, ages 8 to 45 in the phase 3 trial5 | Phase 3 NORTHSTAR trial began dosing in June 20265 | 24-month trial, so results are years away5 | NCT07419334 |
| OCU410ST, Ocugen. Modifier gene therapy | Stargardt disease from any ABCA4 mutation6 | Phase 2/3 GARDian3 fully dosed; an interim review in September 2026 was unfavorable6,7 | Full 8-month data; the company still lists 2027 for results7 | NCT05956626 |
| MCO-010 (sonpiretigene isteparvovec), Nanoscope. Optogenetic gene therapy | Severe central vision loss, any gene8 | Phase 2 STARLIGHT complete in 6 adults9 | Company plans a phase 3 trial10 | NCT05417126 |
| SB-007, SpliceBio. Dual-vector gene therapy | Stargardt disease from ABCA4 mutations11 | Phase 1/2 ASTRA; dose expansion began January 202611 | Safety results; no date announced | NCT06942572 |
| ACDN-01, Ascidian Therapeutics. RNA exon editor | ABCA4-related retinopathy, age 12 and older12 | Phase 1/2 STELLAR; adult dose escalation finished May 202612 | Study expected to run to 203013 | NCT06467344 |
| Emixustat, Kubota Vision. Pill | Macular atrophy from Stargardt disease | Phase 3 SeaSTAR did not meet its main goal14 | None announced | NCT03772665 |
On this page
Tinlarebant is a once-daily pill that lowers the amount of vitamin A carried into the eye. Less vitamin A in the retina means fewer of the toxic by-products, called bisretinoids, that build up and damage the retina in Stargardt disease3. Belite Bio filed its application in June 202615, and on August 11, 2026 the FDA accepted it for priority review with a decision date of February 12, 20273. If it is approved, it will be the first approved treatment for Stargardt disease type 13.
The application rests on the phase 3 DRAGON trial, in which 104 people aged 12 to 20 took tinlarebant 5 mg or a placebo every day for two years4. Areas of lost retina grew 35.7% more slowly with tinlarebant than with placebo16. Visual acuity changed little in either group over the two years17, so the drug is meant to slow damage, not to bring back lost vision. These results are company-reported.
The most common eye side effects came from the way the drug works and were mostly mild: slower adjustment to the dark, a yellow tint to vision (xanthopsia), difficulty seeing at night and sensitivity to light4. Anyone who drives at night should ask about these if the drug is approved.
Gildeuretinol is a modified form of vitamin A designed to form fewer of the toxic by-products without blocking the normal vision cycle5. In the TEASE-1 trial of 50 people with advanced disease, lesions grew 21.6% more slowly over two years than in a comparison group that combined people on placebo with untreated people from a natural-history study18. Its phase 3 NORTHSTAR trial dosed its first patient on June 8, 2026 and aims to enroll about 230 people aged 8 to 45 for 24 months5. The FDA has given it Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations, which speed up development but are not approvals19.
The ABCA4 gene is too large to fit in the standard virus used to carry genes into the eye, which is why gene therapy for Stargardt disease has lagged behind other inherited retinal diseases20. Three different ways around that problem are now being tested in people.
Ocugen’s OCU410ST does not replace ABCA4. It delivers a different gene, RORA, meant to calm several disease processes at once, so it is intended for people with any ABCA4 mutation21,6. All 63 people in the phase 2/3 GARDian3 trial had been treated by April 20266. In September 2026, an independent monitoring committee reviewed 26 of them after eight months and found the treatment effect pointing the wrong way. The committee said stopping for futility could be considered, but it recommended following everyone to eight months because lesion sizes at the start differed between the groups7. Ocugen still lists 2027 for results and an application7. An earlier phase 1 trial reported slower lesion growth in treated eyes than in untreated eyes21.
SpliceBio’s SB-007 uses two viruses, each carrying half of the ABCA4 gene. Inside retinal cells, the two halves join to make the full-length protein11. Its phase 1/2 ASTRA trial moved into a larger dose-expansion stage in January 2026, and the first patient in that stage was treated in Oxford11,20. This is still an early safety trial.
Ascidian’s ACDN-01 rewrites the faulty sections of the ABCA4 RNA, the message cells read to make the protein, instead of replacing the gene22. In May 2026 the company finished the adult dose-escalation part of its phase 1/2 STELLAR trial and opened the study to people over 1212. In November 2026, ClinicalTrials.gov listed the study as active but not recruiting, with completion expected in 203013.
MCO-010 does not fix ABCA4. It makes surviving cells deeper in the retina respond to light, so it is aimed at people who have already lost much of their central vision23. In the phase 2 STARLIGHT study, six adults received one injection into the eye. Average visual acuity improved by 5.5 letters on the eye chart, but there was no comparison group24,9. Nanoscope agreed a phase 3 design with the FDA in 2024 that would include people as young as 128, and in September 2026 it said it planned a phase 3 trial in 202610. The FDA accepted Nanoscope’s application to approve the same therapy for retinitis pigmentosa in September 202632; see our retinitis pigmentosa treatment update.
Emixustat, a pill that slows the vision cycle, did not meet its main or secondary goals in the phase 3 SeaSTAR trial25,14. A later analysis suggested a possible effect in people with smaller lesions, but that analysis was not planned in advance14.
No stem cell treatment has been proven for Stargardt disease. In 2017, doctors reported three women with macular degeneration who were left with severe vision loss after a clinic in Florida injected cells processed from their own fat into both eyes26,27. Be cautious if a clinic asks you to pay for an experimental treatment, offers to treat both eyes on the same day, or points to a ClinicalTrials.gov listing as proof that a treatment works. A listing only means a study was registered27.
The Foundation Fighting Blindness keeps a longer list of earlier-stage Stargardt research28.
Netra Eye Institute offers integrative eye care, including acupuncture, nutrition and lifestyle guidance, Traditional Chinese Medicine and Ayurveda. For Stargardt disease we offer it alongside care from a retina specialist, never instead of it. There is not yet reliable evidence that any of these approaches slows Stargardt disease, and we do not promise that they will improve or preserve vision.
If you are in a clinical trial, or hoping to join one, the trial comes first. Trials can limit supplements and other treatments, so tell the trial team about everything you take before you start anything new. We adjust or pause anything the trial team asks us to. Read more in natural support for Stargardt disease.
No, and no treatment is approved yet1. The first, tinlarebant, is under FDA review with a decision due February 12, 20273. In its main trial it slowed the growth of damaged areas but did not improve vision16,17.
Tinlarebant, a daily pill, is the furthest along: the FDA is reviewing it now3. The newest approaches are gene-based treatments meant to work for any ABCA4 mutation, such as SB-007 and ACDN-01, but they are still in early safety trials11,12.
The FDA’s target date for a decision is February 12, 20273. If it is approved, the label will say who can take it. The main trial enrolled people aged 12 to 204.
Only in trials. OCU410ST is in a phase 2/3 trial whose interim review in September 2026 was unfavorable7, and SB-007 and ACDN-01 are in phase 1/2 trials11,12.
Avoid supplements with more than the recommended daily amount of vitamin A30. A 2018 review found the evidence in people is limited, but many health authorities advise against extra vitamin A for Stargardt disease31.
Get genetic testing first, because most trials select people by gene and stage1,29. Then search ClinicalTrials.gov for “Stargardt”, ask your retina specialist, and follow the Foundation Fighting Blindness research news28.
Please bring your genetic test report, recent retina scans (OCT and autofluorescence), and a list of every supplement you take. Call (732) 503-9999 or use our contact form.
Request a consultation